16 September 2026 editorial review · Item
Encellin thin-film cell encapsulation (ENCRT / ENC-201): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
-
Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. -
Claim check: ENC-103/ENC-201 registry design and status were reviewed. Immune protection and insulin independence are intended outcomes, not demonstrated clinical benefits. No controlled efficacy report was located.
-
Registry NCT06408311: ACTIVE_NOT_RECRUITING; updated 2026-03-11; enrollment 10 (ESTIMATED); primary completion 2026-07-31 (ESTIMATED); results not posted in retrieved record.
-
Primary publication/regulatory sources checked or consulted: PMID 25950860; PMID 28763191; PMID 28632821.
-
Follow-up source correction: the two dead company
/news/URLs moved to/blog/. January company report distinguishes five explants from viable islets in the initial evaluated explant. July ISSCR release reports seven enrolled, non-fibrotic engraftment across seven and islets in multiple participants. Updated item and distinguished the registry estimate of 10 from reported enrollment of seven. These remain interim sponsor/society observations, not controlled efficacy or insulin-independence proof. Removed a redundant secondary citation and unsupported comparative-safety wording. December 2023 financing source remains corporate evidence.